Other studies have identified B7‐H3 in ovarian tumor vessels and found it was associated with adverse clinical outcomes, indicating that tumors may exploit B7‐H3 to downregulate antitumor immunity via T cells. The gene discussed is CD276; the disease is ovarian neoplasm.